Friedreich's Ataxia Treatment Advancement
The Friedreich's Ataxia Research Alliance announced today that BioMarin Pharmaceutical, a company with a strong commitment and success in developing treatments for rare diseases, will be taking the Histone DeACetylase (HDAC) inhibitor program forward. Click here to access FARA's press release as well as a press release from Repligen and BioMarin.
With this exciting news, we are reminded of the important work our donations fund. Thank you to everyone who has had a part in making this happen. We are moving forward to finding a cure for Friedreich's Ataxia!